RDY (64) JAZZ (49) ELAN (45) BMRN (74) ⌘ Pro Terminal →

Summit Therapeutics Inc. (SMMT) — RQD Stock Rating Cockpit

$16.03 -1.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.97

Summit Therapeutics Inc. (SMMT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $12.82B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SMMT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SMMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Summit Therapeutics Inc. (NASDAQ: SMMT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $16.03 (-1.05% 1D, market cap $12.82B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SMMT ranks #453 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SMMT compare to RDY and JAZZ in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SMMT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RDY (Dr. Reddy's Laboratories Ltd) holds a C grade (64/100 RQD, P/E 32.8x, ROIC 9.9%, cap $11.83B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SMMT?

▼

Per SMMT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001599298), Summit Therapeutics Inc. generated $0 in revenue, -$1.08B in net income, and -$323.6M in free cash flow against $751.2M in total assets and $41.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.97 (-0.38%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SMMT)Realized 20D OHLCV Swing Band: ±10.2%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY SMMT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (35% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$15.13+4.6% Next Q

Q2 (-2Q)

Grade E$15.83-0.4% Next Q

Q3 (-1Q)

Grade E$15.77+1.6% Next Q

Current

Grade D-$16.03-7.4% Hist 90D α

Trajectory: E (32) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SMMT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SMMT currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.24) and Max Pain ($16.83) forces dealer call-delta covering toward $30.69.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SMMT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SMMT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

50.530 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

26.00>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE23% OF RANGE

L: $12$16.03H: $29

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on SMMT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -2.50% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 26.00 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (30)

13/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like SMMT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SMMT)

✓Walkthrough of SMMT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SMMT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -5.59%📐 HORIZONTAL RANGE

2026-11-03O $16.20H $16.20L $16.03C $16.03VOL 3.51M

RES: $20.97SUP: $11.49SMA50: $16.24SMA200: $16.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SMMT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SMMT Butterfly Map → + Track SMMT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

26.2%/yr Implied 5Y Growth

vs. +11.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SMMT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SMMT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SMMT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SMMT)

Health Care Rank #453 of 1016 ⚔️ RDY vs SMMT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SMMT vs. RDY, JAZZ, ELAN, BMRN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Summit Therapeutics Inc. (SMMT) ranks #453 by composite RQD confidence (40/100, grade D-) and #88 by equity capitalization ($12.82B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with SMMT at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SMMT ACTIVE Summit Therapeutics Inc.	D-	40/100	—	—	-35.0%	-1.05%	$12.82B	Benchmark Subject
RDY Dr. Reddy's Laboratories Ltd	C	64/100	32.8x	—	9.9%	+0.43%	$11.83B	/rdy-vs-smmt →
JAZZ Jazz Pharmaceuticals plc (Ireland)	D	49/100	—	—	-4.7%	+3.92%	$14.02B	/jazz-vs-smmt →
ELAN Elanco Animal Health Incorporated	D	45/100	—	55.0%	-2.5%	-0.77%	$11.52B	/elan-vs-smmt →
BMRN BioMarin Pharmaceutical Inc.	B	74/100	31.9x	77.7%	6.0%	+1.77%	$11.33B	/bmrn-vs-smmt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001599298

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Summit Therapeutics Inc. (SMMT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$1.08B, operating cash flow of -$322.9M, and free cash flow of -$323.6M (-127.5% YoY). On the balance sheet, SMMT closed FY2025 with $751.2M in total assets against $41.5M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$1.08B	-$322.9M	-$323.6M	$751.2M	$41.5M
FY2024 (FY)	2024-12-31	$0	-$221.3M	-$142.1M	-$142.2M	$435.6M	$21.1M
FY2023 (FY)	2023-12-31	$0	-$614.9M	-$76.8M	-$76.8M	$7.13B	$1.67B

3. SMMT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SMMT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SMMT compare to RDY and JAZZ in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SMMT?

Where is SMMT trading relative to its 50-day, 200-day, and 52-week technical levels?

SMMT last traded at $16.03 (-1.05% on volume of 3,508,164 shares), positioning the stock -1.29% below its 50-day simple moving average ($16.24) and -0.87% below its 200-day simple moving average ($16.17). Across its 52-week range of $12.07 to $29.23, SMMT sits at the 23.1% percentile with a 14-day RSI of 50.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($14.39 to $17.67).

SMMT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SMMT stock right now?

Summit Therapeutics Inc. (SMMT) currently earns a Roarable Rating of D- (Sell — SELL) with 40/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is SMMT's 12-month price target and RQD AI Jury consensus?

SMMT's 12-month base price target is $14.73 (range $11.49 to $30.69), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SMMT RQD Cockpit SMMT 12M Forecast SMMT Earnings & Move SMMT Dividends & DRIP SMMT Insiders & 13F SMMT Whale Options SMMT Profit Sankey SMMT News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SMMT — Summit Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:15:19Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SMMT scores 47 out of 100, a D grade, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is -2.5%. For an investor, this pillar signals that the business is not currently generating cash returns on invested capital; valuation rests on expectations rather than present cash output.
Whale / 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. The score sits in the middle of the range, so institutional support is present but not strong enough to offset the fundamental weakness.
Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider conviction signals in the source data.
Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta is 0.97 and the pillar reflects sector sensitivity. A beta near 1.0 means the stock has tracked broad market movement in the source's framing rather than diverging from it.
Forensic Balance Sheet: 14 / 20. Per the Roarable RQD rating, Altman Z is 26, Piotroski F is 5/9, and Debt/Equity is 0.06. This is the strongest pillar and reflects a low-leverage balance sheet, though it does not by itself indicate profitability.

Taken together, the highest-scoring pillar is the balance sheet, while cash generation and insider conviction are weakest. For a prospective investor, the upside case depends on the balance sheet's capacity to fund operations while the business pursues its trial and partnership catalysts; the valuation tradeoff is that forward P/E of 34 is high relative to negative trailing EPS of -1.35, placing weight on future earnings that the source data does not yet demonstrate.

Business

Summit Therapeutics Inc. Common Stock (SMMT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $13.0B. The source data does not specify its products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M in each of FY 2023, FY 2024, and FY 2025.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-1273.9M	$-1079.6M	N/A	$-323.6M	$225.3M	$41.5M
FY 2024	$0.0M	$-226.0M	$-221.3M	N/A	$-142.2M	$104.9M	$21.1M
FY 2023	$0.0M	$-609.6M	$-614.9M	N/A	$-76.8M	N/A	$1667.4M

Per the market data, gross margin is 0%, operating margin is -36.3%, and net margin is -29.8%. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 5/9. Debt/Equity is 0.06 per the Roarable RQD rating, and FY 2025 debt of $41.5M compares with FY 2023 debt of $1667.4M. Cash was $225.3M at the FY 2025 filing.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the headlines include: an AstraZeneca-related deal and trial-focus report (Yahoo Finance); a Bernstein rating reiteration citing trial concerns (Investing.com); an October 13 share decline of 8.61% (TradingKey); and a $2B financing that asks investors for additional authorized shares (Stock Titan). Each item carries a YELLOW light and MARKET WIRE impact label. Risk watch items drawn from these headlines are trial concerns and dilution from the financing. The Butterfly Supply-Chain Graph lists no proprietary signals.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE and there are no butterfly links. No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data. An investor should watch for the financing-driven share issuance referenced in the news feed as a potential dilution channel, but the source does not quantify its effect.

Open Questions

What are SMMT's revenue sources, given reported revenue of $0.0M across three fiscal years while an AstraZeneca-related deal is referenced?
What is the size and terms of the $2B financing, and how many additional authorized shares are requested?
What specific trial concerns prompted the Bernstein rating reiteration?
Why is trailing P/E and EV/EBITDA unavailable, and what would they show given negative earnings?
What institutional holders and insider transactions exist, given that the holders section is empty?

SMMT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Summit Therapeutics Inc. (SMMT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SMMT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 16h ago

Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus

Yahoo Finance report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com • 19h ago

Bernstein reiterates Summit Therapeutics stock rating on trial concerns

Investing.com report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 22h ago

Summit Therapeutics Inc Stock (SMMT) Moved Down by 8.61% on Oct 13: Key Drivers Unveiled

TradingKey report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Summit Therapeutics Inc. Estimates – NASDAQ:SMMT

TradingView report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StockInvest.us • 1d ago

Summit Therapeutics Stock Price Forecast. Should You Buy SMMT?

StockInvest.us report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

A $2B financing leads Summit Therapeutics (SMMT) to ask investors for more authorized shares.

Stock Titan report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Summit Therapeutics (Nasdaq:SMMT) - Stock Analysis

Simply Wall St report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Summit Therapeutics reports survival benefit for cancer drug in trial (SMMT:NASDAQ)

Seeking Alpha report covering Summit Therapeutics Inc. (SMMT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SMMT Bull vs. Bear Conversation Board — What's Your Call at $16.03?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SMMT 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $17.50 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SMMT (D • RQD 47/100) a Buy at $16.20?

Welcome to the SMMT (Summit Therapeutics Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

FO ForensicBear Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.80 (-21.0%)

Spot @ $16.20

Pump the brakes on SMMT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SMMT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Summit Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $19.28 (+19.0%)

Spot @ $16.20

SMMT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SMMT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $16.20 (52-wk range $12.07 - $29.23), any beat on forward guidance forces shorts and underweight funds to chase.